Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.
George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,” said Yanco...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
To End this Pandemic We ’ll Need a Free Vaccine Worldwide
Until we end COVID-19 transmission across the planet, we are likely to keep getting multiple COVID-19 “waves”— that is, rolling, recurrent outbreaks. While no public health expert has a foolproof crystal ball, this scenario of repeated waves means that the likely contours of the next one to two years are now coming into clearer view.
Right now, many countries including Italy, Spain, the United States, and the United Kingdom, are still struggling desperately to put out the initial fire. They are using suppression measures like stay-at-home orders as a fire extinguisher to smother transmission while urgentl...
Source: TIME: Health - April 15, 2020 Category: Consumer Health News Authors: Gavin Yamey Tags: Uncategorized COVID-19 Source Type: news
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
3 Things Frontline Health Workers Need to Battle COVID-19
By Polly Dunford,
President and Chief Executive OfficerApril 13, 2020We are entering week four of the COVID-19 pandemic, which also happens to coincide with World Health Worker Week. Never has there been a more appropriate time to focus on health workers. Rarely have they faced such danger on such a massive scale. We have an obligation to keep frontline health workers everywhere safe, including making sure all have the personal protective equipment, or PPE, they need.All over the world, we’re seeing reports of health workers who are overworked, underequipped, scared. Some are afraid to go home because the...
Source: IntraHealth International - April 13, 2020 Category: International Medicine & Public Health Authors: mnathe Tags: COVID-19 Community Engagement Digital Health Human Resources Management Leadership and Governance Measurement & Analytics Policy Advocacy World Health Worker Week Global health security Source Type: news
Congo Announces New Ebola Case Just Days Before Planned Declaration That Its Outbreak Had Ended
(BENI, Congo) — A new case of the Ebola virus has been confirmed in eastern Congo, just three days before the country expected to declare an end to the outbreak, the World Health Organization said Friday.
The new case was confirmed in Beni, a community that had been an epicenter of the second-deadliest Ebola outbreak in history.
It had been nearly 42 days without a case, and WHO chief Tedros Adhanom Ghebreyesus said Congo’s declaration had been planned for Monday. “We have been preparing for and expecting more cases,” he said, reflecting the caution that mixed with optimism in recent days.
Read mor...
Source: TIME: Health - April 10, 2020 Category: Consumer Health News Authors: Al-Hadji Kudra Maliro and Maria Cheng / AP Tags: Uncategorized Democratic Republic of the Congo Disease News Desk wire Source Type: news
A Drug Developed to Fight Ebola Could Hold Hope for Coronavirus Treatment
Last year, when I visited the town of Beni, in the Democratic Republic of the Congo (DRC), people did not shake hands. Bottles of disinfectant and buckets of chlorinated water were at the entrance of every business. Misinformation spread across social networks and on news-sites, and treatment centers in the northeastern province of North Kivu were being attacked by armed militias.
At the time, Beni was one of the centers of a devastating Ebola outbreak, the second most deadly in world history. According to the World Health Organization, almost 3,500 people were sickened by the virus, and more than 2,000 died, a case fatali...
Source: TIME: Health - April 1, 2020 Category: Consumer Health News Authors: Nicolas Niarchos Tags: Uncategorized COVID-19 Source Type: news
Leading the hunt for a COVID-19 vaccine
Paul Stoffels, J&J ’s Chief Scientific Officer, has given delegates at eyeforpharma’s Barcelona Virtual conference exclusive insights into its rapid progress in the search for a vaccine to the COVID-19 virus. Speaking to Reuters News on day two of the five-day conference, Stoffels said J&J ’s potential vaccine, which has just been chosen as a lead candidate to help tackle the pandemic, could be ready for clinical trials as soon as early September with evidence of its safety and efficacy expected by the end of the year. This means that the first vaccinations could be given in the first quarter of 2021. ...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Leading the hunt for a COVID-19 vaccine
Paul Stoffels, J&J ’s Chief Scientific Officer, has given delegates ateyeforpharma ’s Barcelona Virtual conference exclusive insights into its rapid progress in the search for a vaccine to the COVID-19 virus. Speaking to Reuters News on day two of the five-day conference, Stoffels said J&J ’s potential vaccine, which has just been chosen as a lead candidate to help tackle the pandemic, could be ready for clinical trials as soon as early September with evidence of its safety and efficacy expected by the end of the year. This means that the first vaccinations could be given in the first quarter of 2021. ...
Source: EyeForPharma - April 1, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Race for a Vaccine: Balancing the Promise, the Peril, and the Process
Source: National Academies of Sciences, Engineering, and Medicine. Published: 4/1/2020.
This one-hour, three-minute webinar features experts who discuss the behind-the-scenes reality of vaccine development, from SARS to Ebola, and how we ’re applying that today as we stand on the front lines in our fight to find a vaccine for COVID-19.
(Video or Multimedia) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 1, 2020 Category: International Medicine & Public Health Source Type: news
Neglected Diseases Kill More People than COVID-19 – It’s Time to Address Them
Credit: UNBy Ifeanyi Nsofor and Adaeze OrehABUJA, Mar 30 2020 (IPS) As COVID-19 surges globally and leaves fear and panic in its wake, global efforts are underway to find a cure. Yet, the same level of response is lacking for several other infectious diseases that kill millions annually. These kinds of neglected tropical diseases (NTDs) are a broad group of communicable diseases which affect more than two billion people and cost developing economies billions of dollars every year.
Lassa Fever is an example and is endemic in Nigeria and other West African countries such as Benin, Ghana, Guinea, Liberia, Mali and Sierra ...
Source: IPS Inter Press Service - Health - March 30, 2020 Category: International Medicine & Public Health Authors: Ifeanyi Nsofor and Adaeze Oreh Tags: Global Headlines Health TerraViva United Nations Neglected Tropical Diseases (NTDs) Source Type: news
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
NEW BRUNSWICK, N.J., March 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vac...
Source: Johnson and Johnson - March 30, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
